𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma

✍ Scribed by Teresa Murray Law; Peter Mencel; Robert J. Motzer

Publisher
Springer US
Year
1994
Tongue
English
Weight
158 KB
Volume
12
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II trial of Didemnin B in patients
Phase II trial of Didemnin B in patients with advanced renal cell carcinoma
✍ Robert Motzer; Howard Scher; Dean Bajorin; Cora Sternberg; George J. Bosl πŸ“‚ Article πŸ“… 1990 πŸ› Springer US 🌐 English βš– 115 KB

Twenty-three patients with advanced renal cell cancer were treated with Didemnin B. One partial response was achieved (5070) in 21 evaluable patients. An allergic reaction was noted in four patients including one patient with anaphylaxis. Didemnin B is not recommended in the treatment of renal cell

Phase I trial of interferon Ξ±2b and lipo
Phase I trial of interferon Ξ±2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma
✍ Jonathan S. Goldberg; Manuel Vargas; Alyssa S. Rosmarin; Matthew I. Milowsky; Ni πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 317 KB

## Abstract ## BACKGROUND Studies suggest that retinoic acid (RA) can augment the antitumor effects of interferon‐based therapy in patients with advanced renal cell carcinoma (RC); however, this benefit has not been achieved convincingly using oral formulations of 13‐cis RA and all‐__trans__ RA. L

A Phase II study of irinotecan in patien
A Phase II study of irinotecan in patients with advanced renal cell carcinoma
✍ Karim Fizazi; FrΓ©dΓ©ric Rolland; Christine Chevreau; Jean-Pierre Droz; Dominique πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 71 KB πŸ‘ 3 views

## Abstract ## BACKGROUND Patients with disseminated renal cell carcinoma (RCC) have a poor outcome, and the disease is considered highly resistant to chemotherapy. Irinotecan is an active drug in the treatment of a number of neoplastic diseases and is not concerned with the multidrug‐resistance p

Phase II study of carboplatin and liposo
Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix
✍ Claire F. Verschraegen; John J. Kavanagh; Evelyne Loyer; Diane Bodurka-Bevers; A πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 85 KB πŸ‘ 2 views

## BACKGROUND. The activity of the combination of carboplatin and liposomal doxorubicin was tested in a Phase II study of patients with recurrent cervical carcinoma. ## METHODS. The combination of carboplatin (area under the concentration curve [AUC], 5) and liposomal doxorubicin (Doxil; starti